SCHEMBL25980910

SCHEMBL25980910

Cc1ccc(N(Cc2ccc(C(=O)NOI)cc2)C(=O)N2CCCCC2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.43
HDAC6 Q9UBN7 3/20 0.43
HPGD P15428 3/20 0.40
LMNA P02545 3/20 0.40
KMT2A Q03164 5/20 0.39
MEN1 O00255 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
GLA P06280 1/20 0.37
EPHX2 P34913 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25980896 0.90 RAB9A (0.42) HPGDLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL25980920 0.86 L3MBTL1 (0.42) HDAC1HDAC6HPGDKMT2AMEN1
SCHEMBL25980762 0.80 HDAC1 (0.39) HDAC1HDAC6HPGDLMNAKMT2A
SCHEMBL16211628 0.80 HDAC6 (0.53) HDAC1HDAC6
SCHEMBL16211684 0.77 RAB9A (0.42) HDAC1HDAC6HPGDLMNASMN1; SMN2
SCHEMBL25979283 0.76 SMN1; SMN2 (0.46) HPGDLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL25980975 0.76 DRD4 (0.50) LMNAKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL25979317 0.74 TSHR (0.46) HPGDLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL22218749 0.73 GAA (0.43) HDAC1HDAC6HPGDKMT2AMEN1
SCHEMBL25980746 0.72 TSHR (0.46) HPGDLMNAKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) NR1H2, CFTR, CYP11B2 HDAC1 1635/4885HDAC6 997/4885HPGD 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.